从北交所到港交所，未盈利药企普祺医药寻路资本市场

Core Viewpoint - Beijing Puxi Pharmaceutical Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange after withdrawing its IPO application from the Beijing Stock Exchange, reflecting a strategic shift for unprofitable biotech companies in the current market environment [1][3][6] Company Overview - Puxi Pharmaceutical, established in 2016, focuses on the field of immune inflammation, with its core product being Pumeixin (PG-011) [3][6] - The company has not yet launched any products, with its core product currently in various stages of clinical trials [1][3] Financial Performance - The company reported a cumulative loss exceeding 300 million yuan from 2024 to the first three quarters of 2025, with a net loss of 178.496 million yuan for 2024 and 125 million yuan for the first three quarters of 2025 [2][6] - Puxi Pharmaceutical's revenue was zero for 2022 and 2023, with only 47,200 yuan in revenue from other business activities in 2024 [5][6] Strategic Shift - The decision to switch from the Beijing Stock Exchange to the Hong Kong Stock Exchange is seen as a pragmatic adjustment due to the more stringent review process for unprofitable companies on the former [1][6] - The Hong Kong Stock Exchange's Chapter 18A is designed for unprofitable biotech companies, offering lower listing thresholds and faster access to capital [1][6] Product Development - Pumeixin has two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis, both of which are in advanced clinical trial stages [7][8] - The gel has completed Phase III trials for adults and adolescents, while the nasal spray is in Phase III trials for adults [7] Commercial Collaboration - Puxi Pharmaceutical has signed an exclusive commercialization agreement with Jichuan Pharmaceutical, allowing the latter to market Pumeixin nasal spray in China for up to 1 billion yuan [8][9] - This partnership is expected to provide essential funding and leverage Jichuan's commercial expertise to expedite market entry for Puxi's products [9]